Clinical Trials Logo

Metastases, Neoplasm clinical trials

View clinical trials related to Metastases, Neoplasm.

Filter by:

NCT ID: NCT00041808 Completed - Melanoma Clinical Trials

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

Start date: July 2001
Phase: Phase 1/Phase 2
Study type: Interventional

MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to “stick”, to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon. When DOX is added to MTCs, DOX attaches to the carbon part of the MTCs. MTC-DOX is directed to and deposited in the area of a tumor, where it is thought that it then "leaks" through the blood vessel walls. Once in the surrounding tissues, it is thought that Doxorubicin becomes "free from" the magnetic beads and will then be able to act against the tumor cells. The iron component of the particle has magnetic properties, making it possible to direct MTC-DOX to specific tumor sites in the liver by placing a magnet on the body surface. It is hoped that MTC-DOX used with the magnet may target the chemotherapy drug directly to liver tumors and provide a treatment to patients with cancers that have spread to the liver.

NCT ID: NCT00039780 Completed - Breast Neoplasms Clinical Trials

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

Start date: September 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether BNP7787 is effective in preventing or reducing neurotoxicity (nerve damage) caused by paclitaxel (Taxol®).

NCT ID: NCT00037869 Completed - Clinical trials for Neuroendocrine Tumors

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Start date: November 2001
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors. The safety of this treatment will also be studied.

NCT ID: NCT00037609 Completed - Breast Neoplasms Clinical Trials

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Start date: January 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of the phase I study is to determine a safe dose for combination therapy with capecitabine and exisulind. A secondary objective is to assess pharmacokinetic interactions between the two drugs and assess the biological activity of exisulind. The primary objective of the Phase II part of this study is to assess the anti-tumor activity of this combination therapy measured by objective tumor response. Secondary end points also assessed will be toxicity of therapy, duration of response and time to progression.

NCT ID: NCT00035061 Completed - Urologic Neoplasms Clinical Trials

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Start date: n/a
Phase: Phase 2
Study type: Interventional

Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

NCT ID: NCT00035035 Completed - Clinical trials for Pancreatic Neoplasms

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Start date: n/a
Phase: Phase 3
Study type: Interventional

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

NCT ID: NCT00034918 Completed - Breast Neoplasms Clinical Trials

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

Start date: May 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic breast cancer at 2 dose levels.